Citius Pharmaceuticals (CTXR)

Citius Pharmaceuticals (CTXR) Stock Price & Analysis


CTXR Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.63 - $1.71
Previous Close$0.69
Average Volume (3M)1.16M
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)$33.28M
Total Debt (Recent Filing)$532.88K
Price to Earnings (P/E)-3.3
Dec 13, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding158,857,798
10 Day Avg. Volume644,226
30 Day Avg. Volume1,158,139
Standard Deviation0.30
Financial Highlights & Ratios
Price to Book (P/B)1.24
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Price Target Upside484.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Citius Pharmaceuticals’s price range in the past 12 months?
Citius Pharmaceuticals lowest stock price was $0.63 and its highest was $1.71 in the past 12 months.
    What is Citius Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Citius Pharmaceuticals’s upcoming earnings report date?
    Citius Pharmaceuticals’s upcoming earnings report date is Dec 13, 2023 which is in 74 days.
      How were Citius Pharmaceuticals’s earnings last quarter?
      Citius Pharmaceuticals released its earnings results on Aug 14, 2023. The company reported -$0.06 earnings per share for the quarter, the consensus estimate of -$0.06 by $0.
        Is Citius Pharmaceuticals overvalued?
        According to Wall Street analysts Citius Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Citius Pharmaceuticals pay dividends?
          Citius Pharmaceuticals does not currently pay dividends.
          What is Citius Pharmaceuticals’s EPS estimate?
          Citius Pharmaceuticals’s EPS estimate is -$0.04.
            How many shares outstanding does Citius Pharmaceuticals have?
            Citius Pharmaceuticals has 158,857,800 shares outstanding.
              What happened to Citius Pharmaceuticals’s price movement after its last earnings report?
              Citius Pharmaceuticals reported an EPS of -$0.06 in its last earnings report, expectations of -$0.06. Following the earnings report the stock price went down -6.522%.
                Which hedge fund is a major shareholder of Citius Pharmaceuticals?
                Among the largest hedge funds holding Citius Pharmaceuticals’s share is Gotham Asset Management LLC. It holds Citius Pharmaceuticals’s shares valued at N/A.


                  Citius Pharmaceuticals Stock Smart Score

                  The Citius Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Citius Pharmaceuticals

                  Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.


                  Top 5 ETFs holding CTXR

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Vanguard Russell 3000 ETF
                  Up to five ETFs with an Outperform Smart Score that hold CTXR. The ETFs are listed according to market value of CTXR within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Bio-Path Holdings
                  Eton Pharmaceuticals
                  Fennec Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis